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The potential for interassay carryover is inherent in the design of all random-access analyzers, which perform multiple assays on the same patient's blood sample and transport blood samples and reagents by a dedicated system of probes that is common to all assay protocols.
Interassay carryover consists of residual quantities of assay reagents that have survived a probe wash and are carried by way of these probes into the protocol of a second assay. Of clinical interest are reagent carryovers that cause systematic biases in assay responses. In development and clinical evaluation of any random-access blood analyzer, therefore, all potential sources of interassay carryovers must be investigated. Should a specific interassay carryover be identified, the clinical chemist has two possible courses of action: to label the instrument with the estimated amount of detected carryover, so that an assay is identified for possible inaccuracy or the measured result can be accurately adjusted; or to modify the assay so as to eliminate or substantially reduce the identified carryover (e.g.,
by increasing the volume of the corresponding wash step). The Abbott AxSYM System (Abbott Labs., Abbott Park, IL), a continuous and random-access immunoassay analyzer, utilizes both microparticle enzyme immunoassay (MEIA) and fluorescence polarization immunoassay (FPIA) technologies [1] . The AxSYM system contains two pipette centers, sampling and process, both of which are potential agents of interassay carryover.
In the sampling center, reagents and samples (patients' samples, calibrators, or controls) are transferred by the sampling center pipette into a reaction vessel containing seven wells; also within the sampling center, reagents or samples are sometimes mixed or diluted. The loaded reaction vessel is transferred to the process center, where a second system pipette is used for dilution, mixing, or transferring of reagents and samples.
The problem for Abbott was how to statistically investigate every potential source of interassay carryover that might occur in the sampling or process centers of the AxSYM instrument. Diagrammatic illustrations of the AxSYM system are presented in reference 1.
AxSYM assay protocols vary in their pipetting activities and incubation periods. Within any given AxSYM assay protocol, the pipetting activities are grouped into one to three pipetting blocks (P1, P2, P3) for the processing center and one pipetting block (PS) for the sampling center, all of which are temporally separated by distinct incubation times. The pipetting activities within a pipetting block consist of diluting, mixing, or transferring reagents, samples, or mixtures of samples and reagents. To optimize instrument throughput, the AxSYM software scheduler determines the exact order of occurrence in time of all of the piperting blocks from all of the selected assay protocols. This optimization, which involves shuffling the pipetting blocks of different assay protocols without violating required incubation times, usually includes placing a pipetting block of one assay protocol between the pipetting blocks of other assay protocols. The potential for interassay carryover existed among the 5260 possible permutations of pipetting blocks on the AXSYM system, all of which we had statistically evaluated according to the methodology described in this paper.
We are aware of only one published report that addresses the problem of interassay carryover on random-access devices [12] . The authors of that paper proposed 12-and 27-run designs for [2] , is more economical in that multiple sources of reagent carryovers can be simultaneously evaluated against a single control.
Methodology
For every assay pair selected from all 231 possible pairs of 22 AXSYM assays, one assay was considered as a potential contaminating source (the "con-assay") and the other was considered as potentially susceptible to carryover (the "sus-assay"). 3 Thus, there were 462 (2 X 231) "con"-"sus" assay permutations to consider as potential sources of carryover. The control consisted of the sus-assay preceded by itself to ensure the absence of carryover.
In the first stage of testing, pipetting block sources that were statistically judged to be either within or outside system specifications were eliminated from further study. In this stage, all possible pipetting block sources of carryover from the con-assay into the sus-assay were statistically compared with the control of the sus-assay. Sample sizes were arranged to be sufficiently large that we could be quite certain of (a) detecting most of the zero-bias cases and (b) not misjudging a carryover bias to be inside the system specifications when it was actually outside the system specifications.
In the second stage, pipetting block sources that had been judged to be statistically inconclusive were studied more extensively. sample sizes are determined to be sufficiently large for us to be quite certain that carryover biases actually within the prespecifled limits of indifference (LLI and ULI) will be judged to be within system specifications, and that a carryover bias of magnitude actually greater than or equal to a specification limit (LL or UL) will be judged to be outside the indifference limits. For each con-sus assay pair, pipetting block interactions were evaluated, for convenience, in separate sets of experiments for the sampling and process centers of the AxSYM system. Each of the two experiments had its own sus-assay control.
In the present study, the number of con-sus pipetting block interaction treatments for any given experiment varied between 1 and 9, depending on the product of the number of sus-assay pipetting blocks (1-3) and con-assay pipetting blocks (1-3) being evaluated. Using Dunnett's multiple comparison procedure [2, 3] , we statistically compared each of the con-sus pipetting block treatment combinations within an experiment with the corresponding sus-assay control. When practical, we used the following approximate optimal sample size allocations: equal sample sizes for all p carryover treatments within a specific con-sus pair experiment, with the sus-assay control having \/ times as many replicates as any of the treatments f4J.
In planning the sample sizes for each experiment of p treatments compared with a control, we prepared an instrument loadlist, which specified the pipetting order of the con-and sus-assays. The loadlist was then presented to the instrument, and the software scheduler determined the timeline, i.e., the specific times at which incubations and pipetting blocks of each assay in the loadlist were to occur. Using the statistical methodology given in the Appendix, we analyzed the timeline output by the scheduler to determine whether the resulting replicate sizes of the p con-sus treatments plus the sus-assay control were statistically adequate. If the sample sizes were statistically inadequate, the process was iteratively repeated with a new loadlist.
Usually, the resulting sample sizes of the p treatments could be controlled to be only approximately equal, and the numbers of replicates of the sus-assay control could be manipulated to be only -\/ times the numbers of replicates of any of the p con-sus treatments.
METHODOLOGICAL ASSUMPTIONS
The statistical methodology for the two-stage procedure for estimating interassay carryovers on the AxSYM system is based on the following four assumptions: (a) The average signal response (rate) ratio of a specific con-sus treatment to its control does not change across AXSYM runs; (b) pipetting block sources that are more than one pipetting block removed from a suscep- To illustrate the two-stage testing methodology, we present data generated with the Abbott AxSYM FT.; assay. Pipetting blocks from the AxSYM Digoxin assay were studied as possible sources of carryover into the Fr4 assay. For this example we will use a small subset of the carryover data that were generated from the 5260 possible pipetting block interactions of the AxSYM system. On the basis of historical control data, we chose specification limits of ±0.093 for FT.;, against which the confidence intervals were to be judged. For stage 2 testing, the indifference limits were prespecified to be ±0.073. The digoxin assay requires one pipetting step in the process center (P1) and one in the sampling center (PS), whereas FT'4 has three pipetting steps in the process center (P1, P2, P3) and one pipetting step in the sampling center (PS). Therefore, we had to evaluate three pipetting block interactions in the process center. For experimental convenience, we evaluated the single con-sus pipetting block interaction in the sampling center separately.
Stage 1 sample size calculations (explained in the Appendix)
were based on a historical SD of log-rates of 0.03 7. Using this estimate, we planned the sample sizes such that the joint probability-of accepting all treatments with zero biases and of not accepting (rejecting or determining as being inconclusive) all treatments with biases fixed at the UL (+0.093)-was guaranteed to be at least 0.95 for each of the 2 ( 8) Joint probabilities of accepting treatments with zero biases and not accepting treatments with carryover biases fixed at the upper specification limit.
thus, the corresponding pipetting block interactions were judged to have no significant reagent cross-contaminations. In the sampling center, however, the 98% confidence interval for the pipetting interaction of the digoxtn sampling pipette block (PS) and the FT4 sampling pipette block (PS) contained both 0 and the lower assay specification limit (-0.093). These data were thus judged to be inconclusive, and the PS-PS pipetting block interaction was retested in stage 2. In stage 2, we used a different AxSYM instrument than in stage 1, performing five replicate AxSYM runs of the same loadlist, each including 30 and 14 replicates of the PS-PS treatment and sus-assay control treatments, respectively ( Table  3 ). The optimal allocation of equal replicates for the PS-PS treatment and sus-assay control could not be obtained experimentally.
Using Grubbs' outlier detection procedures [7] , we detected and removed one statistical outlier from the control group of run 1 and one statistical outlier from the con-sus group in run 5. The control group in runs 2, 3, and 4 contained 3, 1, and 3 missing observations, respectively, because of incomplete assays on the instrument. given in the Appendix, we planned the sample sizes for stage 2 such that the probability of judging the PS-PS treatment with a bias fixed at the ULI (+0.073) to be within specifications was at least 0.95, and the probability of judging this treatment to be outside of the limits of indifference with a bias fixed at the UL (+0.093) was at least 0.95 (Table 4) .
The stage 2 data summary in Table  3 shows that the confidence interval around the estimated carryover bias for the PS-PS treatment (-0.007, 0.009) is contained both within the assay specification limits (±0.093) and within the limits of indifference (±0.073). The estimated carryovers in stage 2 were statistically consistent across the five loadlist runs by an analysis of variance test for treatment X run interaction effects (i.e., the F-test for treatment x run interactions was not statistically significant at P = 0.05). This supports the methodological assumption that the average rate ratio from a specific pipetting block interaction treatment to its control does not change (beyond statistical variability) across AxSYIvI runs.
Because all 9 possible within-sus-assay combinations for the processing center (3 piperting blocks X 3 pipetting blocks) existed within the stage 2 FT4 control data, the assumptions of no within-sus-assay reagent carryovers were tested in these data by way of the general linear model for unbalanced data [I41. The control data did not show any statistically detectable pipetting block treatment effects (at P = 0.05 significance), which supported the methodological assumption of no FT.; within-assay reagent carryovers.
The validity of pooling variances across all of the pipetting block combinations and loadlist runs in Tables 2 and 3 was confirmed by separate Bartlett tests for the stage 1 and 2 data [8] (i.e., neither of these Bartlett tests was statistically significant at o Joint probabilities of accepting treatments with biases fixed at the upper limit of indifference and rejecting treatments with carryover biases fixed at the upper specification limit.
The assumption of normality (for Grubbs' outlier detection procedures, Bartlett's test of homogeneous variances, and Dunnett's multiple comparison procedure) was confirmed by Shapiro-%Vilk, skewness, and kurtosis tests f9J of the residuals from dummy variable models [10] fitted to the stage 1 and 2 data, the dummy variables having been created to adjust for possible treatment or loadlist-run effects. None of the aforementioned normality tests of the stage I and 2 data was statistically significant at P = 0.05.
AUSAB EXAMPLE WITH SIMULATED CARRYOVER
To demonstrate the effectiveness of the statistical procedure for detecting carryover on the AxSYM system, we performed an experiment with the AXSYM assay for hepatitis B antibodies (AUSAB), omitting the prewash step to simulate carryover. The con-assay for this experiment was the AxSYM hepatitis B surface antigen (HBsAg) assay. Both the con-and sus-assay pipetting blocks for this experiment were froni the AxSYM sampling center.
The results of this experiment ( When we repeated the experiment for the AUSAB assay with its prescribed 4-mL prewash, the results showed no statistically detectable carryover: The 98% confidence interval contained 0 ( Table 5) .
Discussion
In some cases, it might be more practical for the clinical chemist to improve the wash process than to proceed to stage 2 with an assay for which stage 1 was inconclusive.
The modified assay could then be retested with the stage 1 statistical methodology. This was, in fact, the approach used by Abbott in their carryover studies on AxSYM. In other cases, however, one might want to Sample center (PS) Pooled The selection of the carryover specification limits (LL and UL) is a critical aspect of the methodology.
In selecting these specifications for a given sus-assay, the clinical chemist should consider the maximum amount of carryover bias that can be tolerated. Naturally, there is a trade-off between the size of the specification limits and the required sample sizes: As the magnitude of the specification limits is reduced, the sample sizes required increase. As previously recommended, maintaining the ratio of treatment to control replicates at -_\/ will maximize the power of the multiple comparisons procedure for a given fixed total sample size.
In general, stage I and stage 2 of this methodology should be performed on the same unit because the wash characteristics, and thus the carryovers, may vary across units. Unfortunately, at the time we wanted to use the stage 2 methodology for the VT4 data example, the AxSYM prototype that had been used for stage 1 testing no longer existed, so we had to use a different instrument.
In many applications of the enclosed methodology, we expect that the ratios (t = 1, . 
where [il and ,tt0 are the population means of the con-sus treatment In stage 2, all 2" possible bias configurations are considered with each treatment's carryover bias fixed at either the ULI or the UL. As with stage 1, the stage 2 sample sizes are determined such that, for each of the 2" configurations of carryover biases, the following probability is ensured to be at least 0.95 and ideally at least 0.99: the joint probability of judging all of the treatments corresponding to the p -q biases set at ULI to be within system specifications and of judging all of the treatments corresponding to the q UL biases to be outside the indifference limits, where 0 q p. A lower bound for the stage 2 probability criterion, which Clinical Chemistry 42, No. 5, 1996 
